BPIQ Blog

Dec 9, 20193 min read

Merck acuires Arqule: Non-covalent Btk kinase inhibitors take center stage

Merck (MRK.N) reported today that it is buying ARQL for over a 100% premium from Friday's closing price (https://reut.rs/341eQv1). This...